ArticleCellular & molecular biology letters2026
Persistent PI3K-AKT signaling fortifies cellular defense against oxidative stress and ferroptosis through augmented mitochondrial fitness.
Article in Cellular & molecular biology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic oxidative stress is recognized as a hallmark of cancer and represents a potentially targetable vulnerability in malignant cells. Oncogenic mutations in phosphatidylinositol 3-kinase (PI3K) are frequently observed across diverse malignancies, playing a crucial role in cancer progression. However, the relationship between PI3K–AKT signaling, mitochondrial fitness, and ferroptosis resistance remains poorly understood.
methodsWe compared the sensitivity of MCF-7 cells (harboring oncogenic PI3K activation) and MDA-MB-231 cells with oxidative stress and ferroptosis inducers using high-content imaging analysis and flow cytometry. RNA-sequencing was performed to identify transcriptomic changes following PI3K inhibition. Mitochondrial fitness was assessed by measuring mitochondrial mass, membrane potential, ATP production, and glutathione levels. Functional validation was conducted through pharmacological manipulation using PI3K–AKT–mTOR pathway inhibitors and AKT activators, as well as genetic approaches involving ectopic expression of oncogenic PIK3CA-E542K in HeLa cells.
resultsCancer cells with constitutive PI3K activation exhibited high resistance to oxidative stress and ferroptosis compared with cells without oncogenic PI3K mutations. Mechanistically, PI3K–AKT signaling orchestrated an augmented mitochondrial gene program, enhancing mitochondrial fitness and antioxidant capacity. Inhibition of the PI3K–AKT–mTOR pathway selectively increased reactive oxygen species levels, compromised mitochondrial fitness, induced mitophagy, and sensitized cells with oncogenic PI3K activation to ferroptosis. Conversely, ectopic expression of oncogenic PIK3CA or pharmacological activation of AKT conferred resistance to oxidative stress and ferroptosis in a mitochondria-dependent manner, as evidenced by the abrogation of protective effects upon mitochondrial uncoupling.
conclusionsOur findings establish a novel link between enhanced mitochondrial fitness and ferroptosis resistance in cancer cells with hyperactive PI3K signaling. These results suggest that combining ferroptosis induction with PI3K inhibition and mitochondrial fitness impairment may offer a promising therapeutic strategy for cancers harboring oncogenic PI3K mutations. This approach provides new insights into potential treatment modalities that exploit the interplay between oncogenic signaling pathways and cellular redox homeostasis in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.